RARA Agonists Stratify AML Patients via IRF8 Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
RARA agonists, such as tamibarotene, have shown promise in cancer treatment but have not met their therapeutic potential due to non-selectivity and toxicity, and there is a need to better understand their efficacy and safety in humans, particularly in identifying responsive patient populations.
Innovation Solution
The use of IRF8 biomarkers, including elevated IRF8 mRNA levels and super enhancer association, to stratify patients and predict responsiveness to tamibarotene treatment in non-acute promyelocytic leukemia (APL) acute myelocytic leukemia (AML) and myelodysplastic syndrome (MDS), allowing for targeted administration with agents like decitabine, azacitabine, and arsenic trioxide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RARA agonists are used for cancer treatment, then therapeutic efficacy is improved, but toxicity increases due to non-selectivity
Solution Approach 1:
The patent applies local quality by developing RARA-selective agonists that specifically target the RARA receptor subtype rather than affecting all retinoid receptors uniformly. This selective action concentrates the therapeutic effect on RARA-expressing cancer cells while minimizing off-target effects on other receptor systems, thereby improving the efficacy-toxicity ratio.
2Reliability
If RARA agonists are used for cancer treatment, then anti-cancer activity is improved, but safety deteriorates
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of retinoid compounds to create RARA-selective agonists with altered binding characteristics. These structural modifications change the selectivity parameter of the agonist, enabling preferential binding to RARA over other retinoid receptors, thus enhancing anti-cancer activity while improving safety profile.
3Reliability
If patient populations are stratified using IRF8 biomarkers, then treatment efficacy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies mechanics substitution by replacing complex clinical assessment methods with a molecular biomarker-based diagnostic system. Instead of relying on multiple clinical parameters and subjective evaluations, the invention uses IRF8 mRNA or protein levels as an objective, quantifiable marker to predict response to RARA agonist therapy, simplifying the diagnostic process while improving efficacy prediction.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.